Celsion announces IRB approval to begin clinical study of ThermoDox® in breast cancer
Celsion announces the University Medical Center Utrecht in the Netherlands has received IRB approval to begin a Phase I study to determine safety, tolerability and feasibility of ThermoDox® in combination with MR-HIFU hyperthermia and cyclophosphamide therapy for local treatment of mBC. June 20, 2019